These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 3074865)

  • 1. Clinical pharmacology and pharmacokinetics of fluoxetine: a review.
    Bergstrom RF; Lemberger L; Farid NA; Wolen RL
    Br J Psychiatry Suppl; 1988 Sep; (3):47-50. PubMed ID: 3074865
    [No Abstract]   [Full Text] [Related]  

  • 2. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.
    Beasley CM; Masica DN; Heiligenstein JH; Wheadon DE; Zerbe RL
    J Clin Psychopharmacol; 1993 Oct; 13(5):312-20. PubMed ID: 8227489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of fluoxetine in healthy Mexican subjects.
    Carrasco-Portugal MC; Granados-Soto V; Reyes-García G; Medina-Santillán R; Herrera JE; Flores-Murrieta FJ
    Proc West Pharmacol Soc; 2001; 44():69-70. PubMed ID: 11793998
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers.
    Vlase L; Leucuta A; Farcau D; Nanulescu M
    Biopharm Drug Dispos; 2006 Sep; 27(6):285-9. PubMed ID: 16770757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women.
    Allard S; Sainati S; Roth-Schechter B; MacIntyre J
    Drug Metab Dispos; 1998 Jul; 26(7):617-22. PubMed ID: 9660843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
    Hall J; Naranjo CA; Sproule BA; Herrmann N
    J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents].
    Bertschy G; Vandel S; Perault MC
    Therapie; 1994; 49(6):509-12. PubMed ID: 7878612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
    Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
    Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasmatic concentrations of fluoxetine, pharmacokinetics, therapeutic response and side effects].
    Pérez Sola V; Pérez Blanco J; Alvárez E; Queralto JM
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1993; 21(4):143-7. PubMed ID: 8213289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method to monitor serum concentrations of fluoxetine and its major metabolite for pharmacokinetic studies.
    Franceschi L; Faggiani A; Furlanut M
    J Pharm Biomed Anal; 2009 Feb; 49(2):554-7. PubMed ID: 19117710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions.
    Mathewson MK
    Crit Care Nurse; 1989 Apr; 9(4):84-92. PubMed ID: 2684545
    [No Abstract]   [Full Text] [Related]  

  • 12. Alternatives to structural modeling.
    Veng-Pedersen P
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():49-50. PubMed ID: 9003579
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of fluoxetine.
    Altamura AC; Moro AR; Percudani M
    Clin Pharmacokinet; 1994 Mar; 26(3):201-14. PubMed ID: 8194283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine kinetics and protein binding in normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Pottratz ST; Sloan RS; Wolen RL; Lemberger L
    Clin Pharmacol Ther; 1984 Jul; 36(1):138-44. PubMed ID: 6610522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine: clinical pharmacology and physiologic disposition.
    Lemberger L; Bergstrom RF; Wolen RL; Farid NA; Enas GG; Aronoff GR
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):14-9. PubMed ID: 3871765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fluoxetine.
    Young AH; Ashton CH
    Trends Pharmacol Sci; 1996 Nov; 17(11):400. PubMed ID: 8990954
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.